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Type-2 ribosome-inactivating proteins, composed of a toxic A-chain and lectin-like B-chain, display various biological functions,
including cytotoxicity and immunomodulation. We here cloned the lectin-like B-chain encoding fragment of a newly identiﬁed
type-2 RIP gene, articulatin gene, from Viscum articulatum, into a bacterial expression vector to obtain nonglycosylated
recombinant protein expressed in inclusion bodies. After puriﬁcation and protein refolding, soluble refolded recombinant
articulatin B-chain (rATB) showed lectin activity speciﬁc toward galactoside moiety and was stably maintained while stored in
low ionic strength solution. Despite lacking glycosylation, rATB actively bound leukocytes with preferential binding to monocytes
and in vitro stimulated PBMCs to release cytokines without obvious cytotoxicity. These results implicated such a B-chain fragment
as a potential immunomodulator.
1.Introduction
Ribosome-inactivating proteins (RIPs; EC 3.2.2.22) are
widespread among higher plants of diﬀerent taxonomic
origins and belong to a group of proteins that inhibit
protein synthesis by enzymatically damaging ribosomes [1].
RIPs divide into structural families: type-1 single-chain
proteins with N-β-glycosidase activity and the larger type-
2 consisting of two distinct polypeptide chains. A-chain
of type-2 shows the same enzymatic activity as type-1,
selectively cleaving adenine from rRNA to interrupt inter-
action between elongation Factor II and ribosomes, hence
terminating protein synthesis [2, 3]. Held together with A-
chain by a disulﬁde bridge, B-chain structure is similar to
lectin, speciﬁcally binding galactose, N-acetylgalactosamine,
or N-acetylneuraminic acid. Binding lectin-like B-chain to
carbohydrate moieties on the surface of most eukaryotic
cells allows A-chain entry into cytoplasm, where it is
enzymatically active [4].
Due to their unique structural and functional properties,
some type-2 RIPs with high cytotoxicity have been impli-
cated in cancer therapy and thoroughly examined for ability
to kill cancer cells in vitro or in vivo for decades. One of the
most noticeable is mistletoe lectin I (ML-I), which was iso-
lated from Viscum album and has been identiﬁed as the main
active component of mistletoe extracts, a widely applied
herbal medicine in Europe for complementary treatment
of cancer patients [5]. Interestingly, the possible antitumor
eﬀects of ML-I in animal models are based on its cytotoxic
and immunomodulatory eﬀects [6, 7]; it has also been con-
sidered as an immunomodulator. At subtoxic doses, ML-I, as
well as ricin, has demonstrably enhanced release of cytokines
from peripheral blood mononuclear cells [6, 8]. As ML-I is
composed of an A-chain and a B-chain, clarifying the role2 Evidence-Based Complementary and Alternative Medicine
of each subunit on immunostimulatory eﬀect is needed for
further research. Hajto et al. have demonstrated that the B-
chain binding activity was necessary for immunostimulating
eﬀectsinducedbyML-IandthatML-Iheterodimeraswellas
its isolated B-chain could stimulate immune cells to release
cytokines [6]. Accordingly, it seemed that B-chain alone
was suﬃcient to stimulate immune cells; however, higher
isolated B-chain dose was needed to achieve the same eﬀect
as the ML-I heterodimer. This raises the question of whether
isolatedB-chainwasinfactpureorcontaminatedwithnative
heterodimer during its preparation process. Whether a B-
chain fragment is an active immunomodulator thus remains
questionable. A heterologous expression system, such as E.
coli, can help obtain a pure and adequate amount of B-chain
without heterodimer contamination. Successfully preparing
suchrecombinantB-chainwillfacilitateprobingofbiological
eﬀects and potential use of the B-chain fragment.
Our previous study identiﬁed a new type-2 RIP gene
from a Chinese mistletoe, Viscum articulatum,a n dd e s i g -
nated it as the articulatin gene (GeneBank accession no.
EF620539). This gene shares high sequence homology with
ML-I gene. In this study, we expressed articulatin B-chain
gene in E. coli and created the soluble rATB by an improved
refolding protocol. We kept nonglycosylated rATB stable
during storage for functioning and evaluated its biological
eﬀects on PBMCs.
2.MaterialsandMethods
2.1. Plant Material. Viscum articulatum Burm (Viscoidae,
Loranthaceae sensu lato) was collected and authenticated
by Dr. S.-T. Chiu at Bai Hua Ling, Bao Shan Shi, Yunnan
Province, China (N 24◦43 42.1  ,E9 8 ◦48 19.4  )a ta n
altitude of 2020 m in 2004. It invaded the stem of Castanopsis
sp. The specimen (collection number S.-T. Chiu 08534)
will be deposited at the herbarium (TNM) of the National
Museum of Natural Science, Taichung, Taiwan.
2.2. Bacterial Strains and Plasmids. Escherichia coli XL1
blue (F−ϕ80(lacZ)ΔM15 ΔlacX74 hsdR(rk
−, mk
+) ΔrecA1398
endA1 tonA)a n dB L 2 1[ F −ompT hsdSB(rB
−mB
−) gal dcm
(DE3) pLysS(CamR)] were obtained from Invitrogen. Plas-
mid pCR2.1-TOPO (Invitrogen) was used for cloning and
sequencing, plasmid pET-28a(+) (Novagen) for expression.
2.3. Cloning and Preparation of Recombinant Articulatin
B-Chain Expression Constructs. To clone the type-2 RIP gene
from Viscum articulatum, we designed several primer sets
based on the conserved nucleotide sequences within type-2
RIPs genes. Only one oligonucleotide primer set ampliﬁed a
919-bp DNA fragment of the gene encoding type-2 RIP by
PCR(rAT3:5 -CGCCATCGACGTTACCAATCTG-3 ;rA T4:
5 -ATTGATGATGGTCCCATTGCCC-3 ). The full-length
gene was obtained by chromosome walking (CW) on Viscum
articulatumgenomicDNA using the LAPCR in vitrocloning
kit (Takara, Japan) and the primary primers 5end-CW1 (5 -
AGGGGCGTCGCGGAAAAAGTAGGATTG-3 ) and 3end-
CW1 (5 -GGGGCCAACAATCCACGCAAGTCCAGCAGT-
3 ), and the nested primers 5end-CW2 (5 -TCTGAATGG-
CGACTAAAAGGGAACGAGC-3 ) and 3end-CW2 (5 -
CAGCGACCGGCCATCTTCCTCTTTGC-3 ). The whole
type-2 RIP gene from Viscum articulatum was designated as
articulatin gene (GeneBank accession no. EF620539). Based
on this information, we designed a speciﬁc pair of primers to
amplify the articulatin B-chain gene nucleotide sequences:
sense primer: rATB1 (5 -GGAATTCCATATG GACGATGT-
KACCTG CACTATTTCCG-3 )( NdeI site in bold); anti-
sense primer: rATB2 (5 -ATCCGCTCGAGTTATTAAGGC-
ACCGGAAG CCACATTTG-3 ) (two stop codons, under-
lined; XhoI site in bold).
Ampliﬁed B-chain fragment was digested with NdeIa n d
XhoI,thensubclonedintopET-28a(+)toyieldtheexpression
plasmid pET28arATB. For the convenience of detection and
following puriﬁcation, expression vector encoded recombi-
nant protein fused with vector-encoded His-tag peptide at
the N-terminal site.
2.4. Expression of B-chains in E. coli. The rATB was expressed
in E. coli BL21. An overnight culture of each fresh trans-
formant was diluted 1:100 in 0.5L of fresh Luria-Bertani
medium (LB) containing kanamycin (30μg·mL−1)a n d
incubated at 30◦Ct oa nO D 600 of 0.6-0.7. Isopropyl β-D-
thiogalactoside (1.0mM) was added and culture incubated
for an additional 3-4h to induce expression. Cells were then
harvested by centrifuge at 4000g; resuspended in phosphate-
buﬀered saline (PBS) at pH 7.4, and disrupted by sonication.
Celllysatewascentrifugedat20,000g,pelletandsupernatant
were each analyzed by SDS-PAGE to detect rATB.
2.5. Isolation of rATB from Insoluble Inclusion Bodies. The
pellet from lysate of cells transformed with pET-28a rATB
was washed exhaustively with PBS containing 1% Triton X-
100 to remove adsorbed proteins; rATB was then subjected
to refolding protocol.
2.6. Refolding of rATB. Refolding process was based on mod-
iﬁed protocol as previously described [11]. After isolation
of rATB from inclusion bodies, insoluble protein (2mg/mL)
was dissolved in 2.5mL of solubilization buﬀer (8M urea,
10mM NaCl, 10mM Tris-HCl, pH 8.5). The same volume
of reduction buﬀer (50mM DTT in 50mM Tris-HCl, pH
8.5) was added dropwise to the sample, and the mixture was
incubated at room temperature for 2h. The solution was
then diluted with oxidation buﬀe r( 4Mu r e a ,5m Mc y s t e i n e ,
1mM cystine, 5mM d-Gal, 50mM Tris-Cl, pH 8.5) and
dialyzed against the same buﬀer containing half the urea
concentration of the previous round. During this process,
we changed the dialysis buﬀer every 12h. After complete
removal of urea, solution was concentrated by dialoﬁltration
in a Centriprep 10 apparatus (Amicon). Circular dichroism
(CD) measurements and hemagglutination activity were
used to check extent of refolding. For biological assays,
soluble rATB (0.5mg/mL) was stored in 2.2% glycine buﬀer,
pH 7.4 to maintain its activity. Level of contaminating
lipopolysaccharide (LPS) in puriﬁed protein was determined
by Limulus Amebocyte Lysate Assay (Wako Chemicals USA,
Inc.), and the ﬁnal concentration of LPS (<5ng/mg protein)
added to cell cultures was never more than 25pg/mL.Evidence-Based Complementary and Alternative Medicine 3
2.7. CD Measurements. CD spectra were recorded with an
Aviv202SFCDspectrometer(Lakewood,NJ,USA)from195
to 250nm in quartz cuvettes of 1mm path length, recorded
as an average of three scans. CD spectra were measured in
protein solutions of about 0.05mg/mL in 20mM phosphate
buﬀer, and pH 7.4. CD spectra were obtained in millidegrees
and converted to molar ellipticity. Secondary structure
content was estimated from the CD spectra by CONTIN,
SELCON, and CDSSTR methods [12].
2.8. Hemagglutination Activity Assay. Hemagglutination
activity was measured in a 96-well microtiter plate using
a 2% suspension of human erythrocytes. Each well of the
microtiter plate contained 50μL of 2% erythrocyte suspen-
sion and 50μL of serially diluted rATB. The activity was eval-
uatedbyvisualizingtheminimumamountofproteincausing
agglutination. For hemagglutination inhibition assay, 50μL
of 0.2M sugar solution was added to each well to test its
ability to inhibit hemagglutination activity of rATB. Serially
diluted Gal and GalNAc solutions were used to determine
concentration needed for complete inhibition of rATB.
2.9. Molecular Modeling and Docking. Articulatin B-chain
structure was modeled from the template EML-I (PDB ID:
1OQL) using the program Accelry-MODEL. Ligand and
protein were prepared using program sybyl7.3, preliminary
docking obtained by GOLD 3.1.1 program. For precise
docking, preliminary docking data were further processed
via Glide. Hydrogen bond interactions between protein and
ligand were drawn using PyMoL.
2.10. Blood Donors. All samples were collected from healthy
volunteers. The Ethical Committee of China Medical Uni-
versity approved the present study, with informed consent
obtained from all participants.
2.11. Preparation of Lysed Whole Blood Cells for rATB Binding
Assay and Immunoﬂowcytometric Analysis. The heparinized
whole blood cells were treated with AKC lysis buﬀer to
remove red blood cells, then washed twice and resuspended
in PBS pH 7.4. These lysed whole blood cells, consisting
of leukocytes (1 × 106 cells per mL), were incubated with
500ng/mL rATB in the presence or absence of 50mM Gal
or Man at 4◦C for 30 minutes, followed by immunoﬂow-
cytometric analysis with a FACSCanto Flow cytometer (BD
Biosciences). A mouse anti-His-tag monoclonal antibody
(R&D) which targeted the N-terminal His-tag of rATB
w a su s e da sp r i m a r ya n t i b o d y ,r a b b i ta n t i m o u s ea n t i b o d y
labeled with PE (R&D) as secondary antibody. The rATB
binding to leukocytes was determined by detecting intensity
of ﬂuorescence on diﬀerent leukocyte populations deﬁned
by setting a polygonal gate in forward/sideward scatter dot
plot. These results were analyzed with CellQuest software
(BD Biosciences).
2.12. Preparation of Peripheral Blood Mononuclear Cells
and Cytokine Induction Experiments. PBMCs were isolated
from whole blood by centrifugation through Ficoll-Hypaque
solution (Histopaque-1077) and then resuspended in RPMI
1640 medium (Gibco) supplemented with 10% FCS. PBMCs
(5 × 105 cells/mL, 1mL/well) were treated with rATB
(0.8ng/mL–5μg/mL) or vehicle buﬀer (2.2% glycine buﬀer)
or LPS (25μg/mL, Sigma) in the presence or absence of
Gal or Man, cultured in 24-well tissue plates. After 72h of
culturing, supernatants were harvested and tested for pro-
duction of TNF-α and IL-6 using Human Cytokine Kit (BD
Biosciences). Viability was assessed in parallel in each experi-
mentwithCellTiter96AQueouskit(Promega).Experiments
with polymyxin B (Calbiochem) to block in vitro eﬀects of
endotoxin were carried out by preincubation of rATB with
5mg/mL polymyxin B for lh at room temperature.
2.13. Statistical Analysis. Data are expressed as means ± s.d.
C o m p a r i s o n sw e r em a d eb yt w o - t a i l e dt-tests; signiﬁcance
was accepted at 0.05 level of probability (P<. 05).
3. Results
3.1. Sequence Identiﬁcation and Analysis of the Articulatin
B-Chain Gene. Whole gene encoding for type-2 RIP from
Viscum articulatum was previously cloned as described
in Section 2 and designated the articulatin gene. Based
on alignment with other related type-2 RIP genes, we
delimited gene fragment coding for B-chain. The B-chain
coding sequence of 789bp (263 amino acid residues with
a calculated Mr of 28,877) was ampliﬁed by PCR from
genomic DNA of V. articulatum for sequence determination
and heterologous gene expression. Deduced amino acid
sequencesofarticulatinB-chainhadanexpectedhighoverall
sequence identity level to ML-I B-chain (81%). Alignment of
articulatin sequences, ML-I, and ricin D showed amino acid
residues responsible for sugar binding in ML-I B-chain and
ricin B-chain as conserved or replaced by related residues in
articulatin B-chain (Figure 1).
3.2. Molecular Modeling and Docking Experiments. Due to
inadequate identiﬁcation of native articulatin and fear that
articulatin has an inactive B-chain as previously described
(SNLRP (Sambucus nigra lectin-related protein), a novel
type-2 RIP with an inactive B-chain from Sambucus nigra)
[13], we performed molecular modeling and docking to
examine postulated structure of articulatin B-chain before
rATB expression. The 3D model of the articulatin B-chain
exhibitedoverallfoldingsimilartothatofML-IB-chainused
as template. Simulated structure contained an N- and a C-
terminal carbohydrate binding site. In the best glide-docking
of GalNAc at the C-terminal sugar binding site of articulatin
B-chain, ﬁve amino acid residues—Asp235, Arg238, Ser239,
Asn254, and Asn256—can directly donate hydrogen bonds
to GalNAc (Figure 2), arguing potential carbohydrate bind-
ing capacity of articulatin B-chain with monosaccharide-
binding speciﬁcity toward galactoside moiety.
3.3. Expression and Refolding of Recombinant Articulatin B-
Chain. In light of the potential lectin activity of articulatin
B-chain suggested by modeling and docking, we decided to4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Alignment of deduced amino acid sequence of articulatin B-chain (GeneBank accession no. EF620539), ML-I B-chain (A58957),
and ricin D B-chain (P02879). Residues participating in N- and C-terminal sugar binding sites of the B-chain are indicated by  [9, 10]; •
denoteshighlyconservedresiduesformingahydrophobiccoreofB-chaindomains.Residuesparticipatinginsugarbindingsites,butdistinct
from the conserved residues, are in boldface type. Joined arrows mark Cys residues forming intrachain disulﬁde bonds. Cys residues forming
interchain disulﬁde bond are marked with ◦.P o t e n t i a lN-glycosylation sites are boxed.
Asn254 GalNAc
Asn256 Asn235
Arg238
Ser239
Figure 2: Best glide docking result of GalNAc in C-terminal sugar
binding site of articulatin B-chain. GalNAc binding residues and
GalNAc appear as stick models; red: oxygen; blue: nitrogen; gray:
carbon; yellow dashed lines: hydrogen bonds.
create active rATB to scrutinize potential uses of the B-chain
fragment. We cloned articulatin B-chain gene fragment and
constructed plasmid pET28arATB for expressing rATB in E.
coli BL21, as described in Section 2. Expressed rATB was
totally sequestered in the inclusion bodies fraction. Induc-
tion under various conditions failed to increase solubility of
rATB; however, production of proteins as inclusion bodies
oﬀered the advantage of easy puriﬁcation. Thus, rATB was
puriﬁed by washing the inclusion body fraction with PBS
containing 1% Triton X-100. This process may allow the
isolation of inclusion bodies from other cell components
[14]. Then, these washed inclusion bodies were solubilized
in 8M urea and submitted to the refolding process in the
29
45
66.2
97.4
(
k
D
a
)
123 4 5
rATB
Figure 3: SDS-PAGE (12.5% polyacrylamide gel) of rATB. Lanes:
1: molecular size markers; 2: E. coli BL21 (pET28arATB) prior to
induction; 3: E. coli BL21 (pET28arATB) after induction; 4: 5μg
denatured rATB in inclusion bodies; 5: 1μg refolded soluble rATB.
presence of redox-pair and galactose. Yield of refolded rATB
wasabout32mg/Lculture.SDS-PAGEshowedthemolecular
mass of rATB as approximately 30kDa (Figure 3).
3.4. Stabilization and Monitoring of Soluble Recombinant
Articulatin B-Chain. Previous study has shown that soluble
recombinant ricin B-chain expressed in E. coli,w h i c h
although initially soluble and biologically active, was unsta-
ble and tended to aggregate rapidly [15]. Similarly, we here
observed that soluble refolded rATB gradually aggregatedEvidence-Based Complementary and Alternative Medicine 5
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Figure 4: Monitoring of soluble refolded ATB. (a) Circular dichroism (CD) spectra of rATB after refolding. Protein concentration:
0.05mg/mL. (b) Hemagglutination activity of rATB. Wells: 1 PBS, negative control; 2–4 serially diluted refolded rATB. (c) rATB
hemagglutination inhibition assay. Serially diluted Gal and GalNAc determined concentration needed for total inhibition of 30μg/mL rATB.
and precipitated during dialysis against phosphate buﬀer
saline. We further discovered that the aggregation was
enhanced in the presence of NaCl, which contributed to high
ionic strength. Thus, we here developed isotonic solution
of low ionic strength, 2.2% glycine buﬀer, to keep soluble
refolded rATB stable and active for subsequent functional
assays.
CD analysis was used to monitor protein refolding.
Deconvolution of far-UV CD spectra of refolded rATB
(Figure 4(a)) yielded approximately 20%α-helix and 27%β-
sheet for rATB. Existence of two potential carbohydrate
binding sites led us to perform hemagglutination (HA)
and test rATB lectin activity. Minimum concentration
required for rATB to achieve hemagglutination was around
0.75μg·mL−1 (Figure 4(b)). Hemagglutination test in the
presence of various sugars (hemagglutination inhibition
assay) furthershowed binding speciﬁcity of rATB; D-Gal and
GalNAC completely inhibited rATB at 12mM and 250μM,
respectively, while D-glucose and D-mannose showed no
interaction with rATB, even at 0.2M (Figure 4(c)). Of note,
the lectin activity of rATB remained stable at 4◦C in glycine
buﬀe rf o ro v e ro n ew e e k ,w h e r e a sr A T Bg r a d u a l l yl o s ti t s
activity in 24h while kept in PBS. These results, consistent
withthe predicted lectin activity frommodeling and docking
experiments, revealed stabilized rATB available for future
biological studies.
3.5. Biological Activities of rATB on PBMCs. Stabilization
of rATB allowed us to probe its interactions with immune
cells. Leukocytes from lysed whole blood of healthy vol-
unteers were incubated with rATB in vitro, then analyzed
by immunoﬂowcytometry. Granulocytes, lymphocytes, and
monocytes identiﬁed by setting a polygonal gate in a forward
scatter/sideward scatter dot plot (Figure 5(a)) all showed
binding aﬃnity for rATB, whereas granulocytes and mono-
cytes had higher aﬃnity than lymphocytes (Figure 5(b)).
Presence of the binding inhibitor of rATB, D-galactose,
signiﬁcantly reduced these bindings (Figure 5(c)).
We next explored whether rATB could act as an
immunomodulator. We isolated PBMCs from healthy vol-
unteers and in vitro treated with rATB. In this in vitro culture
system,rATBdose-dependently stimulated PBMCstorelease
TNF-α (Figure 6(a)) and IL-6 (Figure 6(b)). Competitive
(Gal) but not uncompetitive sugar (Man) signiﬁcantly
reduced cytokine release induced by rATB (Figure 6(c)). In
parallel, we performed cell survival assay in each experiment
to evaluate cytotoxicity of rATB. Even at maximum applied
concentration,noobviouscytotoxicity ofrATBwasobserved
(Figure 6(d)).
Since endotoxin can display similar cytokine inducing
eﬀects,weexaminedLPScontaminationinrATBpreparation
using commercially available Limulus Amebocyte Lysate Kit.
In the cytokine induction experiment, LPS contamination
from rATB was lower than 25pg/mL, which had no eﬀect
on this system. Moreover, the presence of polymyxin B
(5μg/mL), an LPS in vitro neutralizer, also had no inﬂuence
on release of cytokines induced by rATB.
4. Discussion
This paper investigates biological functions of new recom-
binant type-2 RIP B-chain, rATB. Lectin activity of rATB
resembles that of other type-2 RIPs: for example, it can
agglutinate red blood cells. This means that it has at least
two binding domains, with rATB binding speciﬁcity to
monosaccharide toward galactoside moiety. In particular,
we ﬁnd preferential binding of rATB to monocytes and
granulocytes similar to that of ML-I [16]; rATB can also6 Evidence-Based Complementary and Alternative Medicine
Granulocytes
Monocytes
Lymphocytes
1023
1023
FSC-A
S
S
C
-
A
0
0
(a)
99.2%
Granulocytes
100 101 102 103 104
100
C
o
u
n
t
s
C
o
u
n
t
s
C
o
u
n
t
s
Monocytes
31.9%
150 Lymphocytes
0
0
0
700
rATB binding
100 101 102 103 104
rATB binding
100 101 102 103 104
rATB binding
99. % 5
(b)
100 101 102 103 104
C
o
u
n
t
s
0
700
rATB binding
100
C
o
u
n
t
s
0
100 101 102 103 104
rATB binding
C
o
u
n
t
s
150
0
100 101 102 103 104
rATB binding
+M a n
+ Gal
+M a n
+ Gal
+ Gal
+M a n
Granulocytes
Monocytes
Lymphocytes
(c)
Figure 5: Binding capability of rATB to diverse leukocytes. Flow cytometric analysis of lysed whole blood after incubation with rATB
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Figure 6: Biological eﬀects of rATB on PBMCs. Relative concentration of TNF-α (a) and IL-6 (b) in culture of PBMCs (5 × 105/mL) treated
with rATB (0.8–5000ng/mL). Data from three individual donors are shown. Measurements were performed in triplicate. Means ± s.d. are
shown. (c) Relative concentration of TNF-α a n dI L - 6i nc u l t u r eo fP B M C s( 5× 105/mL), preincubated with Gal (50mM), Man (50mM), or
vehicle buﬀer before rATB (500ng/mL) treatment. Values shown are averages ± s.d. of one experiment assayed in triplicate. ∗P<. 05 versus
vehicle control. (d) Viability of PBMCs treated with 100–5000ng/mL rATB. The cell viability with vehicle buﬀer treatment is set as 100%.
Values are expressed as the mean of three replicates ± s.d.
increase cytokine secretion from PBMCs in vitro. To the
best of our knowledge, this is the ﬁrst report to show
nonglycosylated recombinant B-chain of type-2 RIP capable
of inducing cytokine release from PBMCs. This ﬁnding is
consistentwithstudiesofisolatedmistletoelectinB-chainon
immunostimulation [6].
Sequence analysis shows articulatin B-chain containing
two N-glycosylation sites. As scarcity of the plant makes
it impossible to obtain enough native protein for analysis,
we currently are unable to clarify the biological role of
protein glycosylation. Prior studies showed N-glycosylation
as important for stability and lectin activity of a ricin B-
chain. Nonglycosylated mutant ricin B-chain rapidly aggre-
gates; even when it appears completely soluble, it is devoid
of sugar binding activity [17, 18]. Similarly, we found
nonglycosylatedrATBgraduallyaggregatingandlosinglectin
activity while stored in solutions of high ionic strength. For
this study we thus developed a solution of low ionic strength
for rATB storage to stabilize activity of rATB. Such long-term
storage stability is obviously critical for research on rATB
andothernonglycosylatedrecombinanttype-2RIPB-chains.
Interestingly, rATB is still active in our in vitro experiments,
where high ionic strength usually exists. This supposes that
rATB can reach its target in time; eﬀect of ligand binding
might also stabilize the protein structure for functioning, as
previously described in [19].
Experiments in animal models suggest that ML-I-
mediated inhibition of tumor growth is associated with8 Evidence-Based Complementary and Alternative Medicine
immunomodulatory eﬃcacy [20]. In a Scid mouse xenograft
model, Thies et al. recently reported low-dose ML-I reducing
melanoma growth and number of metastasis primarily due
to its immunomodulatory eﬀects, while higher dose lost
this eﬀect. One possible mechanism might be that low-
dose mistletoe lectin I increased the number of inﬁltrating
dendritic cells, which can lead to apoptosis of tumor cells;
at a higher dose, ML-I induced apoptosis of dendritic
cells and thus lost its antitumor eﬀect [21]. Based on
this observation, it appears that high cytotoxicity of ML-I
might have a negative eﬀect on stimulating immune cells.
In this study, rATB lacks the toxic A-chain and yet retains
immunostimulating capability without obvious cytotoxicity,
suggesting that this active recombinant B-chain, instead of
heterodimer, might be applied in treatment at a higher dose
to achieve substantial enhancement of immune response
without unwanted cytotoxicity. In this respect, rATB merits
further investigation to ascertain immunomodulatory eﬃ-
cacy and might oﬀer the advantage of a controlled clinically
beneﬁcial immunomodulation in cancer treatment. In sum,
cloning, heterologous expression, refolding, and long-term
storage of rATB have been eﬀectively established. Likewise,
rATB can bind leukocytes and stimulate PBMCs to release
cytokines. Results portend such B-chain fragment as an
immunomodulator.
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RIP: Ribosome-inactivating protein
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